Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29565330 | 1.00 | HPGD (0.50) | HPGDMGLLVNN1CHRNB2CHRNA4 | |
| SCHEMBL23675315 | 0.91 | HPGD (0.51) | HPGDMGLLVNN1ADRA1ADDR1 | |
| SCHEMBL24942718 | 0.91 | HPGD (0.47) | HPGDMGLLVNN1CHRNB2CHRNA4 | |
| SCHEMBL24942913 | 0.89 | HPGD (0.61) | HPGDMGLLVNN1DDR1 | |
| SCHEMBL30201394 | 0.89 | HPGD (0.61) | HPGDMGLLVNN1DDR1 | |
| SCHEMBL23675273 | 0.89 | HPGD (0.51) | HPGDMGLLVNN1ADRA1ADDR1 | |
| SCHEMBL23680713 | 0.89 | HPGD (0.53) | HPGDMGLLVNN1ADRA1ADDR1 | |
| SCHEMBL23675287 | 0.89 | HPGD (0.48) | HPGDMGLLVNN1ADRA1ADDR1 | |
| SCHEMBL23680729 | 0.88 | HPGD (0.64) | HPGDMGLLCHRNB2CHRNA4 | |
| SCHEMBL23675129 | 0.88 | HPGD (0.51) | HPGDMGLLVNN1ADRA1ADDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117377668-A | Inhalant formulations of PGDH inhibitors and methods of use thereof | 迈欧伏特治疗公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-4228650-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | Epirium Bio Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-115335043-A | PGDH inhibitors and methods of making and using | 迈欧伏特治疗公司 | 2022-11-11 | — | — | CN | disclosed |
| WO-2022082009-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | EPIRIUM BIO INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022082009-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | EPIRIUM BIO INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021151014-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
| WO-2021151014-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |